EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Progestin-primed ovarian stimulation with letrozole using different doses of medroxyprogesterone acetate per day: a retrospective cohort study

Hai-Long Li, Bei-Bei Shen, Zheng-Liang He, Hai-Li Wang, Zhi-Feng Sun

Frontiers in Endocrinology · 2024

DOI: 10.3389/fendo.2024.1429338 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Endocrinology, 2024. Verfasst von Hai-Long Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medicine Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China. Hauptthemen laut MEDLINE: Ovulation Induction, Medroxyprogesterone Acetate, Letrozole, Progestins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the progestin-primed ovarian stimulation protocol, the oral administration of medroxyprogesterone acetate has been observed to effectively inhibit the LH surge during ovarian stimulation in patients experiencing infertility. Nevertheless, the use of utilizing medroxyprogesterone acetate during ovarian stimulation can result in more pronounced pituitary suppression, potentially necessitating increased doses of gonadotropins and extended treatment durations. Therefore, it is necessary to determine the optimal dose of medroxyprogesterone acetate, aiming to use relatively lower concentrations of medroxyprogesterone acetate to effectively and safely suppress early LH surges.

Method

This retrospective cohort study included 710 patients who underwent cycles of in vitro fertilization or intracytoplasmic sperm injection and were subjected the progestin-primed ovarian stimulation protocol utilizing letrozole between from 1st January 2021 to 31st December 2021. The study population was divided into low, medium, and high concentration groups based on the daily dosage of medroxyprogesterone acetate.The primary focus of this investigation was on the cumulative live birth rate. Secondary outcomes encompassed the occurrence of a premature surge in luteinizing hormone, the quantity of retrieved oocytes, viable embryos, and high-quality embryos, as well as clinical pregnancy rate, abortion rate, ectopic pregnancy rate, and multiple pregnancy rate.

Results

In this study, significant differences were observed among three groups in various parameters including body mass index, baseline levels of Anti-Müllerian hormone and luteinizing hormone, antral follicle count, total dose of gonadotropin, and duration of gonadotropin administration (p<0.05). The number of oocytes and viable embryos were significantly higher in medium group and higher than those in the low dose group. Following adjustments for confounding factors related to medroxyprogesterone acetate for various outcome measures, we conducted multiple regression analysis to investigate the independent effects of daily medroxyprogesterone acetate dosage within the combined progestin-primed ovarian stimulation and letrozole protocol. Following multivariable regression analysis, no disparities were found in embryo characteristics (number of oocytes retrieved, number of available embryos, number of high-quality embryos) or pregnancy outcomes (clinical pregnancy rate, cumulative live birth rate) among the three groups.

Conclusion

Progestin-primed ovarian stimulation with letrozole using different dose of medroxyprogesterone acetate per day was comparable in terms of the number of oocytes retrieved, the number of high-quality embryos, clinical pregnancy rate and cumulative live birth rate after frozen embryo transfer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovulation InductionMedroxyprogesterone AcetateLetrozoleProgestinsPregnancy RateHumansFemaleRetrospective StudiesAdultPregnancyFertilization in VitroCohort StudiesDose-Response Relationship, Drug

Stichwörter der Autor:innen

ClbRPPOScontrolled ovarian stimulationletrozolemedroxyprogesterone acetate

Substanzen

Medroxyprogesterone AcetateLetrozoleProgestins

Autor:innen und Institutionen

  • Reproductive Medicine Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
  • Hubei Key Laboratory of Embryonic Stem Cell Research, Shiyan, China.
  • Biomedical Engineering College, Hubei University of Medicine, Shiyan, China.
  • The Third Medical School, Hubei University of Medicine, Shiyan, China.
  • Hubei Clinical Research Center For Reproductive Medicine, Shiyan, Hubei, China.

Zitieren

APA

Li, H. L., Shen, B. B., He, Z. L., Wang, H. L., & Sun, Z. F. (2024). Progestin-primed ovarian stimulation with letrozole using different doses of medroxyprogesterone acetate per day: a retrospective cohort study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1429338

Vancouver

Li HL, Shen BB, He ZL, Wang HL, Sun ZF. Progestin-primed ovarian stimulation with letrozole using different doses of medroxyprogesterone acetate per day: a retrospective cohort study. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1429338

BibTeX
@article{Li2024,
  author = {Li, Hai-Long and Shen, Bei-Bei and He, Zheng-Liang and Wang, Hai-Li and Sun, Zhi-Feng},
  title = {Progestin-primed ovarian stimulation with letrozole using different doses of medroxyprogesterone acetate per day: a retrospective cohort study},
  journal = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1429338}
}
Kostenlos starten →